CA2461491A1 - Methods of screening for antagonists of apm1/gzip - Google Patents

Info

Publication number

CA2461491A1

CA2461491A1 CA002461491A CA2461491A CA2461491A1 CA 2461491 A1 CA2461491 A1 CA 2461491A1 CA 002461491 A CA002461491 A CA 002461491A CA 2461491 A CA2461491 A CA 2461491A CA 2461491 A1 CA2461491 A1 CA 2461491A1

Authority

CA

Canada

Prior art keywords

polypeptide

gzip

polypeptides

sequence

insulin

Prior art date

2001-10-05

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Links

• Espacenet
• Global Dossier
• CIPO
• Discuss

• 238000000034 method Methods 0.000 title claims description 211
• 101150096655 APM1 gene Proteins 0.000 title description 32
• 101100162826 Dictyostelium discoideum apm2 gene Proteins 0.000 title description 32
• 239000005557 antagonist Substances 0.000 title description 12
• 238000012216 screening Methods 0.000 title description 4
• 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 596
• 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 580
• 229920001184 polypeptide Polymers 0.000 claims abstract description 574
• 108091033319 polynucleotide Proteins 0.000 claims description 184
• 239000002157 polynucleotide Substances 0.000 claims description 184
• 102000040430 polynucleotide Human genes 0.000 claims description 184
• 239000012634 fragment Substances 0.000 claims description 162
• 150000001413 amino acids Chemical class 0.000 claims description 134
• 239000000203 mixture Substances 0.000 claims description 96
• 239000013598 vector Substances 0.000 claims description 68
• 235000021588 free fatty acids Nutrition 0.000 claims description 49
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 17
• 230000000295 complement effect Effects 0.000 claims description 14
• 150000001875 compounds Chemical class 0.000 abstract description 75
• 230000002503 metabolic effect Effects 0.000 abstract description 52
• 238000011282 treatment Methods 0.000 abstract description 35
• 206010020772 Hypertension Diseases 0.000 abstract description 20
• 208000037765 diseases and disorders Diseases 0.000 abstract description 18
• 206010012601 diabetes mellitus Diseases 0.000 abstract description 12
• 201000001320 Atherosclerosis Diseases 0.000 abstract description 10
• 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 10
• 238000011160 research Methods 0.000 abstract description 4
• 230000005180 public health Effects 0.000 abstract description 2
• 208000030159 metabolic disease Diseases 0.000 abstract 2
• 230000009286 beneficial effect Effects 0.000 abstract 1
• 210000004027 cell Anatomy 0.000 description 179
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 156
• 235000001014 amino acid Nutrition 0.000 description 146
• 229940024606 amino acid Drugs 0.000 description 131
• 230000000694 effects Effects 0.000 description 131
• 108090000623 proteins and genes Proteins 0.000 description 114
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 109
• 239000002773 nucleotide Substances 0.000 description 87
• 125000003729 nucleotide group Chemical group 0.000 description 87
• 102000004877 Insulin Human genes 0.000 description 78
• 108090001061 Insulin Proteins 0.000 description 78
• 229940125396 insulin Drugs 0.000 description 78
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 72
• 229960001031 glucose Drugs 0.000 description 72
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 71
• 239000008103 glucose Substances 0.000 description 71
• 102000004169 proteins and genes Human genes 0.000 description 69
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 64
• 235000018102 proteins Nutrition 0.000 description 64
• 206010022489 Insulin Resistance Diseases 0.000 description 62
• 230000027455 binding Effects 0.000 description 47
• 230000014509 gene expression Effects 0.000 description 47
• 241000282414 Homo sapiens Species 0.000 description 46
• 230000001965 increasing effect Effects 0.000 description 44
• 125000003275 alpha amino acid group Chemical group 0.000 description 43
• 241001465754 Metazoa Species 0.000 description 42
• 150000007523 nucleic acids Chemical class 0.000 description 41
• 150000002632 lipids Chemical class 0.000 description 36
• 239000003795 chemical substances by application Substances 0.000 description 35
• 210000002381 plasma Anatomy 0.000 description 35
• 102000039446 nucleic acids Human genes 0.000 description 34
• 108020004707 nucleic acids Proteins 0.000 description 34
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 33
• 208000008589 Obesity Diseases 0.000 description 32
• 201000010099 disease Diseases 0.000 description 32
• 208000035475 disorder Diseases 0.000 description 32
• 238000006467 substitution reaction Methods 0.000 description 32
• 101150112998 ADIPOQ gene Proteins 0.000 description 31
• 102100031786 Adiponectin Human genes 0.000 description 31
• 101100053794 Homo sapiens ZBTB7C gene Proteins 0.000 description 31
• 238000001727 in vivo Methods 0.000 description 31
• 235000020824 obesity Nutrition 0.000 description 31
• 238000003556 assay Methods 0.000 description 29
• 108020004414 DNA Proteins 0.000 description 28
• 208000002705 Glucose Intolerance Diseases 0.000 description 26
• 238000000338 in vitro Methods 0.000 description 26
• 241000124008 Mammalia Species 0.000 description 25
• 230000003647 oxidation Effects 0.000 description 25
• 238000007254 oxidation reaction Methods 0.000 description 25
• 201000009104 prediabetes syndrome Diseases 0.000 description 25
• 210000004369 blood Anatomy 0.000 description 23
• 239000008280 blood Substances 0.000 description 23
• 235000019197 fats Nutrition 0.000 description 23
• NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 23
• 108010077695 lipolysis-stimulated receptor Proteins 0.000 description 23
• 210000003205 muscle Anatomy 0.000 description 23
• 102000016267 Leptin Human genes 0.000 description 22
• 108010092277 Leptin Proteins 0.000 description 22
• 239000003814 drug Substances 0.000 description 22
• 229940039781 leptin Drugs 0.000 description 22
• 238000000746 purification Methods 0.000 description 22
• 238000002560 therapeutic procedure Methods 0.000 description 22
• 210000001519 tissue Anatomy 0.000 description 22
• 208000016261 weight loss Diseases 0.000 description 22
• 235000005911 diet Nutrition 0.000 description 21
• 230000004071 biological effect Effects 0.000 description 20
• 230000037396 body weight Effects 0.000 description 20
• 230000003247 decreasing effect Effects 0.000 description 20
• 230000001235 sensitizing effect Effects 0.000 description 20
• 230000004580 weight loss Effects 0.000 description 20
• 230000007423 decrease Effects 0.000 description 19
• 125000000539 amino acid group Chemical group 0.000 description 18
• 238000002360 preparation method Methods 0.000 description 18
• 238000012217 deletion Methods 0.000 description 17
• 230000037430 deletion Effects 0.000 description 17
• 229940122199 Insulin secretagogue Drugs 0.000 description 16
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 16
• 230000000378 dietary effect Effects 0.000 description 16
• 239000003446 ligand Substances 0.000 description 16
• 235000012054 meals Nutrition 0.000 description 16
• 235000013336 milk Nutrition 0.000 description 16
• 239000008267 milk Substances 0.000 description 16
• 210000004080 milk Anatomy 0.000 description 16
• 108020003175 receptors Proteins 0.000 description 16
• 102000005962 receptors Human genes 0.000 description 16
• 230000001105 regulatory effect Effects 0.000 description 16
• 230000000890 antigenic effect Effects 0.000 description 15
• 210000004899 c-terminal region Anatomy 0.000 description 15
• 239000013604 expression vector Substances 0.000 description 15
• 108020001507 fusion proteins Proteins 0.000 description 15
• 102000037865 fusion proteins Human genes 0.000 description 15
• 208000019622 heart disease Diseases 0.000 description 15
• 238000004519 manufacturing process Methods 0.000 description 15
• 229920001223 polyethylene glycol Polymers 0.000 description 15
• 238000000638 solvent extraction Methods 0.000 description 15
• 239000000126 substance Substances 0.000 description 15
• 108091026890 Coding region Proteins 0.000 description 14
• 108090001030 Lipoproteins Proteins 0.000 description 14
• 102000004895 Lipoproteins Human genes 0.000 description 14
• 108010076504 Protein Sorting Signals Proteins 0.000 description 14
• 241000699670 Mus sp. Species 0.000 description 13
• 230000008859 change Effects 0.000 description 13
• 238000009472 formulation Methods 0.000 description 13
• 210000004185 liver Anatomy 0.000 description 13
• 230000000291 postprandial effect Effects 0.000 description 13
• 241000894007 species Species 0.000 description 13
• 241000282412 Homo Species 0.000 description 12
• 241000699666 Mus <mouse, genus> Species 0.000 description 12
• 206010028980 Neoplasm Diseases 0.000 description 12
• 239000002202 Polyethylene glycol Substances 0.000 description 12
• 239000002299 complementary DNA Substances 0.000 description 12
• 230000002163 immunogen Effects 0.000 description 12
• UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 12
• 108091028043 Nucleic acid sequence Proteins 0.000 description 11
• 108700019146 Transgenes Proteins 0.000 description 11
• 229940079593 drug Drugs 0.000 description 11
• 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 11
• 238000012360 testing method Methods 0.000 description 11
• 210000000577 adipose tissue Anatomy 0.000 description 10
• 239000002537 cosmetic Substances 0.000 description 10
• 230000004190 glucose uptake Effects 0.000 description 10
• 210000005075 mammary gland Anatomy 0.000 description 10
• 108020004999 messenger RNA Proteins 0.000 description 10
• -1 muscle Chemical compound 0.000 description 10
• 239000000047 product Substances 0.000 description 10
• 210000002966 serum Anatomy 0.000 description 10
• 208000011580 syndromic disease Diseases 0.000 description 10
• 230000009261 transgenic effect Effects 0.000 description 10
• 241000283973 Oryctolagus cuniculus Species 0.000 description 9
• 238000007792 addition Methods 0.000 description 9
• 239000000556 agonist Substances 0.000 description 9
• 239000000427 antigen Substances 0.000 description 9
• 108091007433 antigens Proteins 0.000 description 9
• 102000036639 antigens Human genes 0.000 description 9
• 201000011510 cancer Diseases 0.000 description 9
• 238000002347 injection Methods 0.000 description 9
• 239000007924 injection Substances 0.000 description 9
• 125000005647 linker group Chemical group 0.000 description 9
• 201000010065 polycystic ovary syndrome Diseases 0.000 description 9
• 239000000243 solution Substances 0.000 description 9
• 150000003626 triacylglycerols Chemical class 0.000 description 9
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
• 206010052895 Coronary artery insufficiency Diseases 0.000 description 8
• 206010019280 Heart failures Diseases 0.000 description 8
• 201000001431 Hyperuricemia Diseases 0.000 description 8
• 208000006011 Stroke Diseases 0.000 description 8
• 230000001580 bacterial effect Effects 0.000 description 8
• 150000001720 carbohydrates Chemical class 0.000 description 8
• 238000011161 development Methods 0.000 description 8
• 230000003902 lesion Effects 0.000 description 8
• 208000013441 ocular lesion Diseases 0.000 description 8
• 230000002093 peripheral effect Effects 0.000 description 8
• 230000002265 prevention Effects 0.000 description 8
• 231100001028 renal lesion Toxicity 0.000 description 8
• 239000000523 sample Substances 0.000 description 8
• 230000001225 therapeutic effect Effects 0.000 description 8
• 241000283690 Bos taurus Species 0.000 description 7
• 208000032841 Bulimia Diseases 0.000 description 7
• 206010006550 Bulimia nervosa Diseases 0.000 description 7
• 206010006895 Cachexia Diseases 0.000 description 7
• 108020004705 Codon Proteins 0.000 description 7
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 7
• 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 7
• 208000022531 anorexia Diseases 0.000 description 7
• 210000002459 blastocyst Anatomy 0.000 description 7
• 230000015556 catabolic process Effects 0.000 description 7
• 206010061428 decreased appetite Diseases 0.000 description 7
• 238000006731 degradation reaction Methods 0.000 description 7
• 238000005516 engineering process Methods 0.000 description 7
• 230000002068 genetic effect Effects 0.000 description 7
• 238000003205 genotyping method Methods 0.000 description 7
• 210000001624 hip Anatomy 0.000 description 7
• 238000002744 homologous recombination Methods 0.000 description 7
• 230000006801 homologous recombination Effects 0.000 description 7
• 239000002502 liposome Substances 0.000 description 7
• 239000000463 material Substances 0.000 description 7
• 230000001404 mediated effect Effects 0.000 description 7
• 229930182817 methionine Natural products 0.000 description 7
• 230000009467 reduction Effects 0.000 description 7
• 238000006722 reduction reaction Methods 0.000 description 7
• 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 7
• 241000283707 Capra Species 0.000 description 6
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 6
• 241001494479 Pecora Species 0.000 description 6
• 229930006000 Sucrose Natural products 0.000 description 6
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
• 241000700605 Viruses Species 0.000 description 6
• 230000001594 aberrant effect Effects 0.000 description 6
• 230000008512 biological response Effects 0.000 description 6
• 235000014633 carbohydrates Nutrition 0.000 description 6
• 239000013611 chromosomal DNA Substances 0.000 description 6
• 239000003623 enhancer Substances 0.000 description 6
• 208000015181 infectious disease Diseases 0.000 description 6
• 230000003993 interaction Effects 0.000 description 6
• 210000001161 mammalian embryo Anatomy 0.000 description 6
• 239000011159 matrix material Substances 0.000 description 6
• 230000004048 modification Effects 0.000 description 6
• 238000012986 modification Methods 0.000 description 6
• 238000002823 phage display Methods 0.000 description 6
• HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 6
• 230000008488 polyadenylation Effects 0.000 description 6
• 230000004044 response Effects 0.000 description 6
• 230000028327 secretion Effects 0.000 description 6
• 239000007787 solid Substances 0.000 description 6
• 230000004936 stimulating effect Effects 0.000 description 6
• 239000005720 sucrose Substances 0.000 description 6
• 208000024891 symptom Diseases 0.000 description 6
• 238000001890 transfection Methods 0.000 description 6
• 238000012546 transfer Methods 0.000 description 6
• 208000030507 AIDS Diseases 0.000 description 5
• 229920002307 Dextran Polymers 0.000 description 5
• 208000002249 Diabetes Complications Diseases 0.000 description 5
• 241000196324 Embryophyta Species 0.000 description 5
• 241000238631 Hexapoda Species 0.000 description 5
• LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 5
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
• 239000004365 Protease Substances 0.000 description 5
• 241000700159 Rattus Species 0.000 description 5
• 208000017442 Retinal disease Diseases 0.000 description 5
• 206010038923 Retinopathy Diseases 0.000 description 5
• 239000002253 acid Substances 0.000 description 5
• 230000004913 activation Effects 0.000 description 5
• 235000004279 alanine Nutrition 0.000 description 5
• 230000004075 alteration Effects 0.000 description 5
• 238000013459 approach Methods 0.000 description 5
• 239000002775 capsule Substances 0.000 description 5
• 239000000969 carrier Substances 0.000 description 5
• 238000004113 cell culture Methods 0.000 description 5
• 238000004590 computer program Methods 0.000 description 5
• 238000001514 detection method Methods 0.000 description 5
• 230000037213 diet Effects 0.000 description 5
• 210000002919 epithelial cell Anatomy 0.000 description 5
• 230000003631 expected effect Effects 0.000 description 5
• 230000006870 function Effects 0.000 description 5
• 230000004927 fusion Effects 0.000 description 5
• 230000012010 growth Effects 0.000 description 5
• 238000001802 infusion Methods 0.000 description 5
• 230000002401 inhibitory effect Effects 0.000 description 5
• 230000002608 insulinlike Effects 0.000 description 5
• 230000037356 lipid metabolism Effects 0.000 description 5
• 239000003550 marker Substances 0.000 description 5
• 238000002703 mutagenesis Methods 0.000 description 5
• 231100000350 mutagenesis Toxicity 0.000 description 5
• 230000035772 mutation Effects 0.000 description 5
• 201000001119 neuropathy Diseases 0.000 description 5
• 230000007823 neuropathy Effects 0.000 description 5
• 239000002245 particle Substances 0.000 description 5
• 208000033808 peripheral neuropathy Diseases 0.000 description 5
• 230000036470 plasma concentration Effects 0.000 description 5
• 229920000642 polymer Polymers 0.000 description 5
• 102000054765 polymorphisms of proteins Human genes 0.000 description 5
• 230000010076 replication Effects 0.000 description 5
• 230000001177 retroviral effect Effects 0.000 description 5
• 238000010561 standard procedure Methods 0.000 description 5
• 238000013268 sustained release Methods 0.000 description 5
• 239000012730 sustained-release form Substances 0.000 description 5
• 238000013519 translation Methods 0.000 description 5
• 230000014616 translation Effects 0.000 description 5
• 229960001641 troglitazone Drugs 0.000 description 5
• GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 5
• GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 5
• 241000701161 unidentified adenovirus Species 0.000 description 5
• 241000701447 unidentified baculovirus Species 0.000 description 5
• 241001430294 unidentified retrovirus Species 0.000 description 5
• 230000003612 virological effect Effects 0.000 description 5
• 230000004584 weight gain Effects 0.000 description 5
• 108010010803 Gelatin Proteins 0.000 description 4
• 206010060378 Hyperinsulinaemia Diseases 0.000 description 4
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
• 206010033307 Overweight Diseases 0.000 description 4
• 241000288906 Primates Species 0.000 description 4
• RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
• 108020005067 RNA Splice Sites Proteins 0.000 description 4
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
• 150000007513 acids Chemical class 0.000 description 4
• 230000009471 action Effects 0.000 description 4
• 230000002788 anti-peptide Effects 0.000 description 4
• 230000015572 biosynthetic process Effects 0.000 description 4
• 210000004556 brain Anatomy 0.000 description 4
• 238000004422 calculation algorithm Methods 0.000 description 4
• 235000014113 dietary fatty acids Nutrition 0.000 description 4
• 239000000539 dimer Substances 0.000 description 4
• 210000002257 embryonic structure Anatomy 0.000 description 4
• 230000007717 exclusion Effects 0.000 description 4
• 229930195729 fatty acid Natural products 0.000 description 4
• 239000000194 fatty acid Substances 0.000 description 4
• 150000004665 fatty acids Chemical class 0.000 description 4
• 229920000159 gelatin Polymers 0.000 description 4
• 239000008273 gelatin Substances 0.000 description 4
• 235000019322 gelatine Nutrition 0.000 description 4
• 235000011852 gelatine desserts Nutrition 0.000 description 4
• 238000002873 global sequence alignment Methods 0.000 description 4
• 238000004128 high performance liquid chromatography Methods 0.000 description 4
• 230000003451 hyperinsulinaemic effect Effects 0.000 description 4
• 201000008980 hyperinsulinism Diseases 0.000 description 4
• 238000002513 implantation Methods 0.000 description 4
• 150000002576 ketones Chemical class 0.000 description 4
• 210000005229 liver cell Anatomy 0.000 description 4
• 239000000546 pharmaceutical excipient Substances 0.000 description 4
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
• 239000013615 primer Substances 0.000 description 4
• 230000008569 process Effects 0.000 description 4
• 230000000580 secretagogue effect Effects 0.000 description 4
• 238000002864 sequence alignment Methods 0.000 description 4
• 239000003381 stabilizer Substances 0.000 description 4
• 238000003786 synthesis reaction Methods 0.000 description 4
• 230000008685 targeting Effects 0.000 description 4
• 239000013638 trimer Substances 0.000 description 4
• 239000013603 viral vector Substances 0.000 description 4
• 235000019786 weight gain Nutrition 0.000 description 4
• FFEKJBVVAJTQST-WLHGVMLRSA-N (e)-but-2-enedioic acid;1,1-dimethyl-2-(2-morpholin-4-ylphenyl)guanidine Chemical group OC(=O)\C=C\C(O)=O.CN(C)C(N)=NC1=CC=CC=C1N1CCOCC1 FFEKJBVVAJTQST-WLHGVMLRSA-N 0.000 description 3
• FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 3
• 241000282472 Canis lupus familiaris Species 0.000 description 3
• RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 3
• 206010053547 Congenital generalised lipodystrophy Diseases 0.000 description 3
• 201000006705 Congenital generalized lipodystrophy Diseases 0.000 description 3
• 102000053602 DNA Human genes 0.000 description 3
• 241000702421 Dependoparvovirus Species 0.000 description 3
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 3
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
• 206010056997 Impaired fasting glucose Diseases 0.000 description 3
• 208000031773 Insulin resistance syndrome Diseases 0.000 description 3
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
• 241000713869 Moloney murine leukemia virus Species 0.000 description 3
• 108091034117 Oligonucleotide Proteins 0.000 description 3
• 108700026244 Open Reading Frames Proteins 0.000 description 3
• 108091005804 Peptidases Proteins 0.000 description 3
• 241000283984 Rodentia Species 0.000 description 3
• 229920002472 Starch Polymers 0.000 description 3
• 108091081024 Start codon Proteins 0.000 description 3
• 241000282898 Sus scrofa Species 0.000 description 3
• JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 3
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
• 102100021144 Zinc-alpha-2-glycoprotein Human genes 0.000 description 3
• 101710201241 Zinc-alpha-2-glycoprotein Proteins 0.000 description 3
• 239000004480 active ingredient Substances 0.000 description 3
• 210000001789 adipocyte Anatomy 0.000 description 3
• 239000000443 aerosol Substances 0.000 description 3
• 238000001042 affinity chromatography Methods 0.000 description 3
• 230000002776 aggregation Effects 0.000 description 3
• 238000004220 aggregation Methods 0.000 description 3
• QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 3
• 238000004458 analytical method Methods 0.000 description 3
• 238000010171 animal model Methods 0.000 description 3
• 210000004436 artificial bacterial chromosome Anatomy 0.000 description 3
• 230000008901 benefit Effects 0.000 description 3
• 239000001506 calcium phosphate Substances 0.000 description 3
• 229910000389 calcium phosphate Inorganic materials 0.000 description 3
• 235000011010 calcium phosphates Nutrition 0.000 description 3
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
• 238000005119 centrifugation Methods 0.000 description 3
• 238000006243 chemical reaction Methods 0.000 description 3
• 229960001761 chlorpropamide Drugs 0.000 description 3
• 238000004587 chromatography analysis Methods 0.000 description 3
• 210000000349 chromosome Anatomy 0.000 description 3
• YZFWTZACSRHJQD-UHFFFAOYSA-N ciglitazone Chemical compound C=1C=C(CC2C(NC(=O)S2)=O)C=CC=1OCC1(C)CCCCC1 YZFWTZACSRHJQD-UHFFFAOYSA-N 0.000 description 3
• 229950009226 ciglitazone Drugs 0.000 description 3
• 238000003776 cleavage reaction Methods 0.000 description 3
• 230000001276 controlling effect Effects 0.000 description 3
• 208000029078 coronary artery disease Diseases 0.000 description 3
• 238000012937 correction Methods 0.000 description 3
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
• 230000007547 defect Effects 0.000 description 3
• 230000001419 dependent effect Effects 0.000 description 3
• 238000001212 derivatisation Methods 0.000 description 3
• 238000003745 diagnosis Methods 0.000 description 3
• 239000000839 emulsion Substances 0.000 description 3
• 210000003743 erythrocyte Anatomy 0.000 description 3
• 230000001610 euglycemic effect Effects 0.000 description 3
• 210000003527 eukaryotic cell Anatomy 0.000 description 3
• 238000000605 extraction Methods 0.000 description 3
• 239000000499 gel Substances 0.000 description 3
• 238000010353 genetic engineering Methods 0.000 description 3
• 229960004580 glibenclamide Drugs 0.000 description 3
• 229960004346 glimepiride Drugs 0.000 description 3
• WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 3
• 229960001381 glipizide Drugs 0.000 description 3
• ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 3
• ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 3
• 239000000710 homodimer Substances 0.000 description 3
• 210000005260 human cell Anatomy 0.000 description 3
• 210000004408 hybridoma Anatomy 0.000 description 3
• 230000002209 hydrophobic effect Effects 0.000 description 3
• 201000010066 hyperandrogenism Diseases 0.000 description 3
• 230000003053 immunization Effects 0.000 description 3
• 238000002649 immunization Methods 0.000 description 3
• 238000003018 immunoassay Methods 0.000 description 3
• 230000001976 improved effect Effects 0.000 description 3
• 230000006698 induction Effects 0.000 description 3
• 230000001939 inductive effect Effects 0.000 description 3
• 230000000977 initiatory effect Effects 0.000 description 3
• 238000003780 insertion Methods 0.000 description 3
• 230000037431 insertion Effects 0.000 description 3
• 230000003914 insulin secretion Effects 0.000 description 3
• 230000010354 integration Effects 0.000 description 3
• 208000022215 lipoatrophic diabetes Diseases 0.000 description 3
• 201000009099 lipoatrophic diabetes mellitus Diseases 0.000 description 3
• 210000004962 mammalian cell Anatomy 0.000 description 3
• 238000005259 measurement Methods 0.000 description 3
• XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical group CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 3
• 229960003105 metformin Drugs 0.000 description 3
• 238000000520 microinjection Methods 0.000 description 3
• 239000000178 monomer Substances 0.000 description 3
• 210000000663 muscle cell Anatomy 0.000 description 3
• 230000009826 neoplastic cell growth Effects 0.000 description 3
• 230000007935 neutral effect Effects 0.000 description 3
• 210000000287 oocyte Anatomy 0.000 description 3
• 230000002611 ovarian Effects 0.000 description 3
• 239000008194 pharmaceutical composition Substances 0.000 description 3
• 229960005095 pioglitazone Drugs 0.000 description 3
• 239000013612 plasmid Substances 0.000 description 3
• 239000000843 powder Substances 0.000 description 3
• 238000001742 protein purification Methods 0.000 description 3
• 230000006337 proteolytic cleavage Effects 0.000 description 3
• 238000010188 recombinant method Methods 0.000 description 3
• 210000003296 saliva Anatomy 0.000 description 3
• 150000003839 salts Chemical class 0.000 description 3
• 230000007017 scission Effects 0.000 description 3
• 238000007423 screening assay Methods 0.000 description 3
• 230000003248 secreting effect Effects 0.000 description 3
• 210000002363 skeletal muscle cell Anatomy 0.000 description 3
• 210000001082 somatic cell Anatomy 0.000 description 3
• 235000019698 starch Nutrition 0.000 description 3
• 210000000130 stem cell Anatomy 0.000 description 3
• 235000000346 sugar Nutrition 0.000 description 3
• YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical compound OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 3
• 239000000725 suspension Substances 0.000 description 3
• 229960002277 tolazamide Drugs 0.000 description 3
• OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 3
• 229960005371 tolbutamide Drugs 0.000 description 3
• 238000013518 transcription Methods 0.000 description 3
• 230000035897 transcription Effects 0.000 description 3
• 230000009466 transformation Effects 0.000 description 3
• 230000032258 transport Effects 0.000 description 3
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
• 210000002700 urine Anatomy 0.000 description 3
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
• KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
• 206010067484 Adverse reaction Diseases 0.000 description 2
• 229920000936 Agarose Polymers 0.000 description 2
• 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 2
• 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 2
• 241000271566 Aves Species 0.000 description 2
• 241000894006 Bacteria Species 0.000 description 2
• 125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
• VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
• 208000024172 Cardiovascular disease Diseases 0.000 description 2
• 102000014914 Carrier Proteins Human genes 0.000 description 2
• 108010078791 Carrier Proteins Proteins 0.000 description 2
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
• 206010011878 Deafness Diseases 0.000 description 2
• 102000004190 Enzymes Human genes 0.000 description 2
• 108090000790 Enzymes Proteins 0.000 description 2
• 241000283086 Equidae Species 0.000 description 2
• 241000282326 Felis catus Species 0.000 description 2
• 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
• 108010093488 His-His-His-His-His-His Proteins 0.000 description 2
• 108060003951 Immunoglobulin Proteins 0.000 description 2
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
• 125000000729 N-terminal amino-acid group Chemical group 0.000 description 2
• 229930193140 Neomycin Natural products 0.000 description 2
• 108091006006 PEGylated Proteins Proteins 0.000 description 2
• 108090000526 Papain Proteins 0.000 description 2
• 108010067902 Peptide Library Proteins 0.000 description 2
• 108010007127 Pulmonary Surfactant-Associated Protein D Proteins 0.000 description 2
• 102100027845 Pulmonary surfactant-associated protein D Human genes 0.000 description 2
• 108020004511 Recombinant DNA Proteins 0.000 description 2
• 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
• 241000714474 Rous sarcoma virus Species 0.000 description 2
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
• 241000282887 Suidae Species 0.000 description 2
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
• 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 2
• 208000037063 Thinness Diseases 0.000 description 2
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
• 239000005862 Whey Substances 0.000 description 2
• 102000007544 Whey Proteins Human genes 0.000 description 2
• 108010046377 Whey Proteins Proteins 0.000 description 2
• 230000021736 acetylation Effects 0.000 description 2
• 238000006640 acetylation reaction Methods 0.000 description 2
• 230000006838 adverse reaction Effects 0.000 description 2
• 238000000246 agarose gel electrophoresis Methods 0.000 description 2
• 238000012867 alanine scanning Methods 0.000 description 2
• 125000003277 amino group Chemical group 0.000 description 2
• 239000007864 aqueous solution Substances 0.000 description 2
• 210000001106 artificial yeast chromosome Anatomy 0.000 description 2
• 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 2
• UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
• 230000008499 blood brain barrier function Effects 0.000 description 2
• 210000001218 blood-brain barrier Anatomy 0.000 description 2
• 239000000872 buffer Substances 0.000 description 2
• 229940077731 carbohydrate nutrients Drugs 0.000 description 2
• 230000032823 cell division Effects 0.000 description 2
• 238000007385 chemical modification Methods 0.000 description 2
• 230000002759 chromosomal effect Effects 0.000 description 2
• 230000001268 conjugating effect Effects 0.000 description 2
• 230000021615 conjugation Effects 0.000 description 2
• 230000008878 coupling Effects 0.000 description 2
• 238000010168 coupling process Methods 0.000 description 2
• 238000005859 coupling reaction Methods 0.000 description 2
• 239000000287 crude extract Substances 0.000 description 2
• 230000001351 cycling effect Effects 0.000 description 2
• XVOYSCVBGLVSOL-UHFFFAOYSA-N cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 description 2
• 235000018417 cysteine Nutrition 0.000 description 2
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
• 230000002950 deficient Effects 0.000 description 2
• 230000003111 delayed effect Effects 0.000 description 2
• 239000003085 diluting agent Substances 0.000 description 2
• 238000009826 distribution Methods 0.000 description 2
• 239000002552 dosage form Substances 0.000 description 2
• 238000001962 electrophoresis Methods 0.000 description 2
• 238000004520 electroporation Methods 0.000 description 2
• 229940088598 enzyme Drugs 0.000 description 2
• 230000020764 fibrinolysis Effects 0.000 description 2
• BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
• 238000001476 gene delivery Methods 0.000 description 2
• 210000004602 germ cell Anatomy 0.000 description 2
• 208000004104 gestational diabetes Diseases 0.000 description 2
• 125000005842 heteroatom Chemical group 0.000 description 2
• 239000000833 heterodimer Substances 0.000 description 2
• 102000018358 immunoglobulin Human genes 0.000 description 2
• 229940072221 immunoglobulins Drugs 0.000 description 2
• 230000006872 improvement Effects 0.000 description 2
• 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 2
• 150000002484 inorganic compounds Chemical class 0.000 description 2
• 229910010272 inorganic material Inorganic materials 0.000 description 2
• 238000007912 intraperitoneal administration Methods 0.000 description 2
• 238000001990 intravenous administration Methods 0.000 description 2
• 238000002955 isolation Methods 0.000 description 2
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
• 229960000310 isoleucine Drugs 0.000 description 2
• 238000005304 joining Methods 0.000 description 2
• 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
• 239000008101 lactose Substances 0.000 description 2
• 230000000670 limiting effect Effects 0.000 description 2
• 230000004130 lipolysis Effects 0.000 description 2
• 239000007788 liquid Substances 0.000 description 2
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
• 230000002934 lysing effect Effects 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 239000002609 medium Substances 0.000 description 2
• 239000012528 membrane Substances 0.000 description 2
• 230000004060 metabolic process Effects 0.000 description 2
• JEJGUIDNYBAPGN-UHFFFAOYSA-N methylenedioxydimethylamphetamine Chemical compound CN(C)C(C)CC1=CC=C2OCOC2=C1 JEJGUIDNYBAPGN-UHFFFAOYSA-N 0.000 description 2
• 230000000813 microbial effect Effects 0.000 description 2
• 230000003278 mimic effect Effects 0.000 description 2
• DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
• 229960004927 neomycin Drugs 0.000 description 2
• 230000003472 neutralizing effect Effects 0.000 description 2
• 229940125395 oral insulin Drugs 0.000 description 2
• 150000002894 organic compounds Chemical class 0.000 description 2
• 206010033675 panniculitis Diseases 0.000 description 2
• 229940055729 papain Drugs 0.000 description 2
• 235000019834 papain Nutrition 0.000 description 2
• 238000007911 parenteral administration Methods 0.000 description 2
• 230000036961 partial effect Effects 0.000 description 2
• 230000006320 pegylation Effects 0.000 description 2
• 230000000144 pharmacologic effect Effects 0.000 description 2
• 230000036314 physical performance Effects 0.000 description 2
• 229920002401 polyacrylamide Polymers 0.000 description 2
• 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
• 230000035935 pregnancy Effects 0.000 description 2
• 238000012545 processing Methods 0.000 description 2
• 229960003387 progesterone Drugs 0.000 description 2
• 239000000186 progesterone Substances 0.000 description 2
• 235000019419 proteases Nutrition 0.000 description 2
• 108091008146 restriction endonucleases Proteins 0.000 description 2
• 230000000717 retained effect Effects 0.000 description 2
• FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
• 231100000489 sensitizer Toxicity 0.000 description 2
• 238000000926 separation method Methods 0.000 description 2
• 238000002741 site-directed mutagenesis Methods 0.000 description 2
• 238000000527 sonication Methods 0.000 description 2
• 239000000600 sorbitol Substances 0.000 description 2
• ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
• PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
• 238000003153 stable transfection Methods 0.000 description 2
• 238000010186 staining Methods 0.000 description 2
• 210000004003 subcutaneous fat Anatomy 0.000 description 2
• 150000008163 sugars Chemical class 0.000 description 2
• 230000002459 sustained effect Effects 0.000 description 2
• 231100000419 toxicity Toxicity 0.000 description 2
• 230000001988 toxicity Effects 0.000 description 2
• 230000002103 transcriptional effect Effects 0.000 description 2
• 230000001052 transient effect Effects 0.000 description 2
• 230000014621 translational initiation Effects 0.000 description 2
• 210000004291 uterus Anatomy 0.000 description 2
• 239000003981 vehicle Substances 0.000 description 2
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
• 239000013585 weight reducing agent Substances 0.000 description 2
• BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 1
• MRTPISKDZDHEQI-YFKPBYRVSA-N (2s)-2-(tert-butylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC(C)(C)C MRTPISKDZDHEQI-YFKPBYRVSA-N 0.000 description 1
• NPDBDJFLKKQMCM-SCSAIBSYSA-N (2s)-2-amino-3,3-dimethylbutanoic acid Chemical compound CC(C)(C)[C@H](N)C(O)=O NPDBDJFLKKQMCM-SCSAIBSYSA-N 0.000 description 1
• ALBODLTZUXKBGZ-JUUVMNCLSA-N (2s)-2-amino-3-phenylpropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CC1=CC=CC=C1 ALBODLTZUXKBGZ-JUUVMNCLSA-N 0.000 description 1
• DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
• UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
• 229930182837 (R)-adrenaline Natural products 0.000 description 1
• CXCHEKCRJQRVNG-UHFFFAOYSA-N 2,2,2-trifluoroethanesulfonyl chloride Chemical compound FC(F)(F)CS(Cl)(=O)=O CXCHEKCRJQRVNG-UHFFFAOYSA-N 0.000 description 1
• OGNSCSPNOLGXSM-UHFFFAOYSA-N 2,4-diaminobutyric acid Chemical compound NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
• PBBGSZCBWVPOOL-HDICACEKSA-N 4-[(1r,2s)-1-ethyl-2-(4-hydroxyphenyl)butyl]phenol Chemical compound C1([C@H](CC)[C@H](CC)C=2C=CC(O)=CC=2)=CC=C(O)C=C1 PBBGSZCBWVPOOL-HDICACEKSA-N 0.000 description 1
• 102100024959 5-hydroxytryptamine receptor 2C Human genes 0.000 description 1
• 101710138093 5-hydroxytryptamine receptor 2C Proteins 0.000 description 1
• SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
• 102000011690 Adiponectin Human genes 0.000 description 1
• 108010076365 Adiponectin Proteins 0.000 description 1
• 102000006822 Agouti Signaling Protein Human genes 0.000 description 1
• 108010072151 Agouti Signaling Protein Proteins 0.000 description 1
• WQVFQXXBNHHPLX-ZKWXMUAHSA-N Ala-Ala-His Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O WQVFQXXBNHHPLX-ZKWXMUAHSA-N 0.000 description 1
• YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 1
• 108010088751 Albumins Proteins 0.000 description 1
• 102000009027 Albumins Human genes 0.000 description 1
• 102100038920 Alpha-S1-casein Human genes 0.000 description 1
• 208000028185 Angioedema Diseases 0.000 description 1
• 201000005670 Anovulation Diseases 0.000 description 1
• 206010002659 Anovulatory cycle Diseases 0.000 description 1
• BHSYMWWMVRPCPA-CYDGBPFRSA-N Arg-Arg-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CCCN=C(N)N BHSYMWWMVRPCPA-CYDGBPFRSA-N 0.000 description 1
• PTNFNTOBUDWHNZ-GUBZILKMSA-N Asn-Arg-Met Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(O)=O PTNFNTOBUDWHNZ-GUBZILKMSA-N 0.000 description 1
• LJUOLNXOWSWGKF-ACZMJKKPSA-N Asn-Asn-Glu Chemical compound C(CC(=O)O)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)N LJUOLNXOWSWGKF-ACZMJKKPSA-N 0.000 description 1
• KHCNTVRVAYCPQE-CIUDSAMLSA-N Asn-Lys-Asn Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O KHCNTVRVAYCPQE-CIUDSAMLSA-N 0.000 description 1
• FANQWNCPNFEPGZ-WHFBIAKZSA-N Asp-Asp-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O FANQWNCPNFEPGZ-WHFBIAKZSA-N 0.000 description 1
• 244000063299 Bacillus subtilis Species 0.000 description 1
• 235000014469 Bacillus subtilis Nutrition 0.000 description 1
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
• 206010006482 Bronchospasm Diseases 0.000 description 1
• 101000583086 Bunodosoma granuliferum Delta-actitoxin-Bgr2b Proteins 0.000 description 1
• 101100421200 Caenorhabditis elegans sep-1 gene Proteins 0.000 description 1
• 241000282836 Camelus dromedarius Species 0.000 description 1
• 241000282465 Canis Species 0.000 description 1
• 241000282461 Canis lupus Species 0.000 description 1
• 102100032378 Carboxypeptidase E Human genes 0.000 description 1
• 108010058255 Carboxypeptidase H Proteins 0.000 description 1
• 241000700198 Cavia Species 0.000 description 1
• 241000700199 Cavia porcellus Species 0.000 description 1
• 102000000844 Cell Surface Receptors Human genes 0.000 description 1
• 108010001857 Cell Surface Receptors Proteins 0.000 description 1
• 108090000317 Chymotrypsin Proteins 0.000 description 1
• 108091062157 Cis-regulatory element Proteins 0.000 description 1
• 108020004635 Complementary DNA Proteins 0.000 description 1
• 102000036364 Cullin Ring E3 Ligases Human genes 0.000 description 1
• 239000003155 DNA primer Substances 0.000 description 1
• 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
• 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
• 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
• 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
• 201000005948 Donohue syndrome Diseases 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 238000012286 ELISA Assay Methods 0.000 description 1
• 102100031780 Endonuclease Human genes 0.000 description 1
• 241000701867 Enterobacteria phage T7 Species 0.000 description 1
• 241000283074 Equus asinus Species 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• 241000588724 Escherichia coli Species 0.000 description 1
• 108060002716 Exonuclease Proteins 0.000 description 1
• 108091006020 Fc-tagged proteins Proteins 0.000 description 1
• 241000282324 Felis Species 0.000 description 1
• 241000724791 Filamentous phage Species 0.000 description 1
• 241000287828 Gallus gallus Species 0.000 description 1
• 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
• 241000713813 Gibbon ape leukemia virus Species 0.000 description 1
• NUSWUSKZRCGFEX-FXQIFTODSA-N Glu-Glu-Cys Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CS)C(O)=O NUSWUSKZRCGFEX-FXQIFTODSA-N 0.000 description 1
• 102400000321 Glucagon Human genes 0.000 description 1
• 108060003199 Glucagon Proteins 0.000 description 1
• 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
• 108010051815 Glutamyl endopeptidase Proteins 0.000 description 1
• SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
• 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
• 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
• 108010023302 HDL Cholesterol Proteins 0.000 description 1
• 101710154606 Hemagglutinin Proteins 0.000 description 1
• 208000009889 Herpes Simplex Diseases 0.000 description 1
• 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
• 101000741048 Homo sapiens Alpha-S1-casein Proteins 0.000 description 1
• 101150013372 Htr2c gene Proteins 0.000 description 1
• 102000002265 Human Growth Hormone Human genes 0.000 description 1
• 108010000521 Human Growth Hormone Proteins 0.000 description 1
• 239000000854 Human Growth Hormone Substances 0.000 description 1
• 241000701109 Human adenovirus 2 Species 0.000 description 1
• 241001135569 Human adenovirus 5 Species 0.000 description 1
• PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
• 241000282620 Hylobates sp. Species 0.000 description 1
• 206010020710 Hyperphagia Diseases 0.000 description 1
• 208000001953 Hypotension Diseases 0.000 description 1
• IOVUXUSIGXCREV-DKIMLUQUSA-N Ile-Leu-Phe Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 IOVUXUSIGXCREV-DKIMLUQUSA-N 0.000 description 1
• TUYOFUHICRWDGA-CIUDSAMLSA-N Ile-Met Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(O)=O)CCSC TUYOFUHICRWDGA-CIUDSAMLSA-N 0.000 description 1
• IPFKIGNDTUOFAF-CYDGBPFRSA-N Ile-Val-Arg Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IPFKIGNDTUOFAF-CYDGBPFRSA-N 0.000 description 1
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
• 206010022714 Intestinal ulcer Diseases 0.000 description 1
• SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
• AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
• FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 1
• ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
• RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
• XIGSAGMEBXLVJJ-YFKPBYRVSA-N L-homocitrulline Chemical compound NC(=O)NCCCC[C@H]([NH3+])C([O-])=O XIGSAGMEBXLVJJ-YFKPBYRVSA-N 0.000 description 1
• SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
• 102000008192 Lactoglobulins Human genes 0.000 description 1
• 108010060630 Lactoglobulins Proteins 0.000 description 1
• 208000009481 Laryngeal Edema Diseases 0.000 description 1
• 206010023845 Laryngeal oedema Diseases 0.000 description 1
• 208000035369 Leprechaunism Diseases 0.000 description 1
• 108010036940 Levansucrase Proteins 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• 101150110867 MC4R gene Proteins 0.000 description 1
• 241000713862 Moloney murine sarcoma virus Species 0.000 description 1
• 241000713333 Mouse mammary tumor virus Species 0.000 description 1
• 241001529936 Murinae Species 0.000 description 1
• 241000714177 Murine leukemia virus Species 0.000 description 1
• 238000005481 NMR spectroscopy Methods 0.000 description 1
• RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
• 208000025047 Non-histaminic angioedema Diseases 0.000 description 1
• 239000004677 Nylon Substances 0.000 description 1
• 108010038807 Oligopeptides Proteins 0.000 description 1
• 102000015636 Oligopeptides Human genes 0.000 description 1
• AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
• UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
• 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
• 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 102100026466 POU domain, class 2, transcription factor 3 Human genes 0.000 description 1
• 101710084413 POU domain, class 2, transcription factor 3 Proteins 0.000 description 1
• 102000057297 Pepsin A Human genes 0.000 description 1
• 108090000284 Pepsin A Proteins 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• 108010043958 Peptoids Proteins 0.000 description 1
• KIQUCMUULDXTAZ-HJOGWXRNSA-N Phe-Tyr-Tyr Chemical compound N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O KIQUCMUULDXTAZ-HJOGWXRNSA-N 0.000 description 1
• 101710182846 Polyhedrin Proteins 0.000 description 1
• 208000037062 Polyps Diseases 0.000 description 1
• 208000004880 Polyuria Diseases 0.000 description 1
• 239000004372 Polyvinyl alcohol Substances 0.000 description 1
• 108010069820 Pro-Opiomelanocortin Proteins 0.000 description 1
• 239000000683 Pro-Opiomelanocortin Substances 0.000 description 1
• 102100027467 Pro-opiomelanocortin Human genes 0.000 description 1
• 108090000544 Proprotein convertase 1 Proteins 0.000 description 1
• 102000004085 Proprotein convertase 1 Human genes 0.000 description 1
• 101710176177 Protein A56 Proteins 0.000 description 1
• 108010029485 Protein Isoforms Proteins 0.000 description 1
• 102000001708 Protein Isoforms Human genes 0.000 description 1
• 102100029796 Protein S100-A10 Human genes 0.000 description 1
• 101710110950 Protein S100-A10 Proteins 0.000 description 1
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
• 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
• 206010061481 Renal injury Diseases 0.000 description 1
• LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
• QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
• 241000712909 Reticuloendotheliosis virus Species 0.000 description 1
• 206010038997 Retroviral infections Diseases 0.000 description 1
• 241000607142 Salmonella Species 0.000 description 1
• 108010077895 Sarcosine Proteins 0.000 description 1
• QMCDMHWAKMUGJE-IHRRRGAJSA-N Ser-Phe-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O QMCDMHWAKMUGJE-IHRRRGAJSA-N 0.000 description 1
• XZKQVQKUZMAADP-IMJSIDKUSA-N Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(O)=O XZKQVQKUZMAADP-IMJSIDKUSA-N 0.000 description 1
• DKGRNFUXVTYRAS-UBHSHLNASA-N Ser-Ser-Trp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O DKGRNFUXVTYRAS-UBHSHLNASA-N 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• 241000256251 Spodoptera frugiperda Species 0.000 description 1
• 238000000692 Student's t-test Methods 0.000 description 1
• 239000004098 Tetracycline Substances 0.000 description 1
• COYHRQWNJDJCNA-NUJDXYNKSA-N Thr-Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O COYHRQWNJDJCNA-NUJDXYNKSA-N 0.000 description 1
• 108010022394 Threonine synthase Proteins 0.000 description 1
• 102000006601 Thymidine Kinase Human genes 0.000 description 1
• 108020004440 Thymidine kinase Proteins 0.000 description 1
• 102000004357 Transferases Human genes 0.000 description 1
• 108090000992 Transferases Proteins 0.000 description 1
• 108090000631 Trypsin Proteins 0.000 description 1
• 102000004142 Trypsin Human genes 0.000 description 1
• 101710175014 Tubby protein Proteins 0.000 description 1
• YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 1
• ARJASMXQBRNAGI-YESZJQIVSA-N Tyr-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N ARJASMXQBRNAGI-YESZJQIVSA-N 0.000 description 1
• 208000024780 Urticaria Diseases 0.000 description 1
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
• 208000036142 Viral infection Diseases 0.000 description 1
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
• 210000000683 abdominal cavity Anatomy 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 230000005856 abnormality Effects 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 239000008186 active pharmaceutical agent Substances 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 239000007801 affinity label Substances 0.000 description 1
• 239000011543 agarose gel Substances 0.000 description 1
• 230000009435 amidation Effects 0.000 description 1
• 238000007112 amidation reaction Methods 0.000 description 1
• 229960002684 aminocaproic acid Drugs 0.000 description 1
• BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
• 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
• 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
• 235000011130 ammonium sulphate Nutrition 0.000 description 1
• AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
• 229960000723 ampicillin Drugs 0.000 description 1
• 210000004102 animal cell Anatomy 0.000 description 1
• 238000005571 anion exchange chromatography Methods 0.000 description 1
• 150000001450 anions Chemical class 0.000 description 1
• 231100000552 anovulation Toxicity 0.000 description 1
• 230000003302 anti-idiotype Effects 0.000 description 1
• 230000005875 antibody response Effects 0.000 description 1
• 239000007900 aqueous suspension Substances 0.000 description 1
• 239000008135 aqueous vehicle Substances 0.000 description 1
• 210000004507 artificial chromosome Anatomy 0.000 description 1
• 125000003118 aryl group Chemical group 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• 208000006673 asthma Diseases 0.000 description 1
• 230000003143 atherosclerotic effect Effects 0.000 description 1
• 230000003416 augmentation Effects 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• 238000002869 basic local alignment search tool Methods 0.000 description 1
• 239000011324 bead Substances 0.000 description 1
• 229940050390 benzoate Drugs 0.000 description 1
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 230000008827 biological function Effects 0.000 description 1
• 239000012472 biological sample Substances 0.000 description 1
• 235000020958 biotin Nutrition 0.000 description 1
• 229960002685 biotin Drugs 0.000 description 1
• 239000011616 biotin Substances 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• 210000001124 body fluid Anatomy 0.000 description 1
• 230000007885 bronchoconstriction Effects 0.000 description 1
• 239000007853 buffer solution Substances 0.000 description 1
• 229910000019 calcium carbonate Inorganic materials 0.000 description 1
• 229910052799 carbon Inorganic materials 0.000 description 1
• 239000001569 carbon dioxide Substances 0.000 description 1
• 229910002092 carbon dioxide Inorganic materials 0.000 description 1
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 239000005018 casein Substances 0.000 description 1
• BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
• 235000021240 caseins Nutrition 0.000 description 1
• 238000012219 cassette mutagenesis Methods 0.000 description 1
• 238000005277 cation exchange chromatography Methods 0.000 description 1
• 230000022131 cell cycle Effects 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 239000001913 cellulose Chemical class 0.000 description 1
• 229920002678 cellulose Chemical class 0.000 description 1
• 235000010980 cellulose Nutrition 0.000 description 1
• 230000003196 chaotropic effect Effects 0.000 description 1
• 238000001311 chemical methods and process Methods 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• 229960005091 chloramphenicol Drugs 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 229960002376 chymotrypsin Drugs 0.000 description 1
• 229960002173 citrulline Drugs 0.000 description 1
• 235000013477 citrulline Nutrition 0.000 description 1
• 230000009194 climbing Effects 0.000 description 1
• 238000010367 cloning Methods 0.000 description 1
• 208000012696 congenital leptin deficiency Diseases 0.000 description 1
• 238000010276 construction Methods 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 229920001577 copolymer Polymers 0.000 description 1
• 238000004132 cross linking Methods 0.000 description 1
• 230000009260 cross reactivity Effects 0.000 description 1
• 239000012228 culture supernatant Substances 0.000 description 1
• 238000012258 culturing Methods 0.000 description 1
• ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
• 239000003405 delayed action preparation Substances 0.000 description 1
• 239000003599 detergent Substances 0.000 description 1
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
• 229960003957 dexamethasone Drugs 0.000 description 1
• 238000002405 diagnostic procedure Methods 0.000 description 1
• 102000004419 dihydrofolate reductase Human genes 0.000 description 1
• 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 238000010494 dissociation reaction Methods 0.000 description 1
• 230000005593 dissociations Effects 0.000 description 1
• 230000006334 disulfide bridging Effects 0.000 description 1
• PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
• 239000003937 drug carrier Substances 0.000 description 1
• 206010013932 dyslexia Diseases 0.000 description 1
• 239000012636 effector Substances 0.000 description 1
• 239000008151 electrolyte solution Substances 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 238000010828 elution Methods 0.000 description 1
• 230000019439 energy homeostasis Effects 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 229960005139 epinephrine Drugs 0.000 description 1
• 229940011871 estrogen Drugs 0.000 description 1
• 239000000262 estrogen Substances 0.000 description 1
• 238000012869 ethanol precipitation Methods 0.000 description 1
• 102000013165 exonuclease Human genes 0.000 description 1
• 238000002474 experimental method Methods 0.000 description 1
• 210000003414 extremity Anatomy 0.000 description 1
• 230000004129 fatty acid metabolism Effects 0.000 description 1
• 239000010685 fatty oil Substances 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 239000012467 final product Substances 0.000 description 1
• 230000037406 food intake Effects 0.000 description 1
• 235000012631 food intake Nutrition 0.000 description 1
• 230000022244 formylation Effects 0.000 description 1
• 238000006170 formylation reaction Methods 0.000 description 1
• 238000005194 fractionation Methods 0.000 description 1
• 108700004026 gag Genes Proteins 0.000 description 1
• 101150098622 gag gene Proteins 0.000 description 1
• 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 238000001502 gel electrophoresis Methods 0.000 description 1
• 230000004077 genetic alteration Effects 0.000 description 1
• 231100000118 genetic alteration Toxicity 0.000 description 1
• 229960004666 glucagon Drugs 0.000 description 1
• MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
• 238000007446 glucose tolerance test Methods 0.000 description 1
• 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
• 125000003147 glycosyl group Chemical group 0.000 description 1
• 230000013595 glycosylation Effects 0.000 description 1
• 238000006206 glycosylation reaction Methods 0.000 description 1
• 239000001963 growth medium Substances 0.000 description 1
• 230000002489 hematologic effect Effects 0.000 description 1
• 239000008241 heterogeneous mixture Substances 0.000 description 1
• 229950001996 hexestrol Drugs 0.000 description 1
• 238000009396 hybridization Methods 0.000 description 1
• 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
• 229920001600 hydrophobic polymer Polymers 0.000 description 1
• 238000012872 hydroxylapatite chromatography Methods 0.000 description 1
• 229960002591 hydroxyproline Drugs 0.000 description 1
• 208000013403 hyperactivity Diseases 0.000 description 1
• 208000006575 hypertriglyceridemia Diseases 0.000 description 1
• 230000036543 hypotension Effects 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 230000008105 immune reaction Effects 0.000 description 1
• 230000005847 immunogenicity Effects 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 230000002458 infectious effect Effects 0.000 description 1
• 206010022000 influenza Diseases 0.000 description 1
• 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
• 239000003112 inhibitor Substances 0.000 description 1
• 230000000968 intestinal effect Effects 0.000 description 1
• 229940028435 intralipid Drugs 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000010255 intramuscular injection Methods 0.000 description 1
• 239000007927 intramuscular injection Substances 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 238000007914 intraventricular administration Methods 0.000 description 1
• 238000004255 ion exchange chromatography Methods 0.000 description 1
• 239000003456 ion exchange resin Substances 0.000 description 1
• 229920003303 ion-exchange polymer Polymers 0.000 description 1
• 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
• FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
• 230000000155 isotopic effect Effects 0.000 description 1
• 230000009191 jumping Effects 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 230000002147 killing effect Effects 0.000 description 1
• 230000006651 lactation Effects 0.000 description 1
• 231100000518 lethal Toxicity 0.000 description 1
• 230000001665 lethal effect Effects 0.000 description 1
• 208000032839 leukemia Diseases 0.000 description 1
• 125000003473 lipid group Chemical group 0.000 description 1
• 229940057995 liquid paraffin Drugs 0.000 description 1
• 210000005228 liver tissue Anatomy 0.000 description 1
• 230000033001 locomotion Effects 0.000 description 1
• 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 238000013507 mapping Methods 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
• 238000010369 molecular cloning Methods 0.000 description 1
• 208000001022 morbid obesity Diseases 0.000 description 1
• 239000005445 natural material Substances 0.000 description 1
• 239000006199 nebulizer Substances 0.000 description 1
• 201000008383 nephritis Diseases 0.000 description 1
• 210000002569 neuron Anatomy 0.000 description 1
• 238000006386 neutralization reaction Methods 0.000 description 1
• 210000002445 nipple Anatomy 0.000 description 1
• 231100000956 nontoxicity Toxicity 0.000 description 1
• 229920001778 nylon Polymers 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• 235000019198 oils Nutrition 0.000 description 1
• 229940049964 oleate Drugs 0.000 description 1
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
• 238000005457 optimization Methods 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 229960003104 ornithine Drugs 0.000 description 1
• 201000008482 osteoarthritis Diseases 0.000 description 1
• 238000005192 partition Methods 0.000 description 1
• 239000008188 pellet Substances 0.000 description 1
• 210000004197 pelvis Anatomy 0.000 description 1
• 229940111202 pepsin Drugs 0.000 description 1
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
• 230000000737 periodic effect Effects 0.000 description 1
• 210000001322 periplasm Anatomy 0.000 description 1
• 230000003285 pharmacodynamic effect Effects 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000008363 phosphate buffer Substances 0.000 description 1
• 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
• 229940080469 phosphocellulose Drugs 0.000 description 1
• 230000026731 phosphorylation Effects 0.000 description 1
• 238000006366 phosphorylation reaction Methods 0.000 description 1
• 230000001766 physiological effect Effects 0.000 description 1
• 239000002504 physiological saline solution Substances 0.000 description 1
• 239000004014 plasticizer Substances 0.000 description 1
• 229920000768 polyamine Polymers 0.000 description 1
• 206010036067 polydipsia Diseases 0.000 description 1
• 238000006116 polymerization reaction Methods 0.000 description 1
• 208000022530 polyphagia Diseases 0.000 description 1
• 229920002451 polyvinyl alcohol Polymers 0.000 description 1
• 230000004481 post-translational protein modification Effects 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 230000002028 premature Effects 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 230000037452 priming Effects 0.000 description 1
• 239000000651 prodrug Substances 0.000 description 1
• 229940002612 prodrug Drugs 0.000 description 1
• 210000001236 prokaryotic cell Anatomy 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• 230000000644 propagated effect Effects 0.000 description 1
• 239000003380 propellant Substances 0.000 description 1
• 238000011321 prophylaxis Methods 0.000 description 1
• 230000012846 protein folding Effects 0.000 description 1
• 230000004853 protein function Effects 0.000 description 1
• 230000029983 protein stabilization Effects 0.000 description 1
• 208000020016 psychiatric disease Diseases 0.000 description 1
• 150000003212 purines Chemical class 0.000 description 1
• 150000003230 pyrimidines Chemical class 0.000 description 1
• 239000011541 reaction mixture Substances 0.000 description 1
• 230000009257 reactivity Effects 0.000 description 1
• 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
• 238000003259 recombinant expression Methods 0.000 description 1
• 238000005932 reductive alkylation reaction Methods 0.000 description 1
• 230000002829 reductive effect Effects 0.000 description 1
• 230000029964 regulation of glucose metabolic process Effects 0.000 description 1
• BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
• 229960003147 reserpine Drugs 0.000 description 1
• 230000000241 respiratory effect Effects 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
• 229960001225 rifampicin Drugs 0.000 description 1
• MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
• 229940043230 sarcosine Drugs 0.000 description 1
• 201000000980 schizophrenia Diseases 0.000 description 1
• 238000004062 sedimentation Methods 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 230000035939 shock Effects 0.000 description 1
• 230000011664 signaling Effects 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• 239000012279 sodium borohydride Substances 0.000 description 1
• 229910000033 sodium borohydride Inorganic materials 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• 239000007901 soft capsule Substances 0.000 description 1
• 238000001179 sorption measurement Methods 0.000 description 1
• 229940063673 spermidine Drugs 0.000 description 1
• 229940063675 spermine Drugs 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 239000007858 starting material Substances 0.000 description 1
• 238000007619 statistical method Methods 0.000 description 1
• 230000010009 steroidogenesis Effects 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 125000001424 substituent group Chemical group 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 239000003826 tablet Substances 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 208000001608 teratocarcinoma Diseases 0.000 description 1
• 229960000814 tetanus toxoid Drugs 0.000 description 1
• 229960002180 tetracycline Drugs 0.000 description 1
• 229930101283 tetracycline Natural products 0.000 description 1
• 235000019364 tetracycline Nutrition 0.000 description 1
• 150000003522 tetracyclines Chemical class 0.000 description 1
• 229940124597 therapeutic agent Drugs 0.000 description 1
• 231100001274 therapeutic index Toxicity 0.000 description 1
• 125000003396 thiol group Chemical group [H]S* 0.000 description 1
• 229940104230 thymidine Drugs 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• 231100000765 toxin Toxicity 0.000 description 1
• 108700012359 toxins Proteins 0.000 description 1
• FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
• 230000005026 transcription initiation Effects 0.000 description 1
• 230000005030 transcription termination Effects 0.000 description 1
• 230000002463 transducing effect Effects 0.000 description 1
• 238000010361 transduction Methods 0.000 description 1
• 230000026683 transduction Effects 0.000 description 1
• 230000001131 transforming effect Effects 0.000 description 1
• 238000003146 transient transfection Methods 0.000 description 1
• 239000012588 trypsin Substances 0.000 description 1
• 229960001322 trypsin Drugs 0.000 description 1
• ZHSGGJXRNHWHRS-VIDYELAYSA-N tunicamycin Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](O)[C@@H](CC(O)[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(NC(=O)C=C2)=O)O)O1)O)NC(=O)/C=C/CC(C)C)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O ZHSGGJXRNHWHRS-VIDYELAYSA-N 0.000 description 1
• MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 1
• 238000010396 two-hybrid screening Methods 0.000 description 1
• 206010048828 underweight Diseases 0.000 description 1
• 241001529453 unidentified herpesvirus Species 0.000 description 1
• 241001515965 unidentified phage Species 0.000 description 1
• 238000012762 unpaired Student’s t-test Methods 0.000 description 1
• 210000000689 upper leg Anatomy 0.000 description 1
• 238000011144 upstream manufacturing Methods 0.000 description 1
• 208000019553 vascular disease Diseases 0.000 description 1
• 208000001319 vasomotor rhinitis Diseases 0.000 description 1
• 230000009385 viral infection Effects 0.000 description 1
• 229920003169 water-soluble polymer Polymers 0.000 description 1
• 230000036642 wellbeing Effects 0.000 description 1
• 238000001262 western blot Methods 0.000 description 1
• 238000002424 x-ray crystallography Methods 0.000 description 1